Comparison
GHRP-2 vs. Triptorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Research other
CAS no.
158861-67-7
57773-63-4
Molecular weight
817.93 g/mol
1311.45 g/mol
Half-life
0.5 h
3 h
Sequence
D-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Mechanism of action
GHRP-2
GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.
Triptorelin
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
4
of which in humans
4
4
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
3